ArticleJournal of experimental & clinical cancer research : CR2020

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.

Liying Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.